Explanations could include (1) the expected result, given no differences in total number of DUs between treatment groups, (2) a lack of sensitivity to change and discriminative value in the current instruments used to assess hand function in SSc and (3) bosentan treatment does not improve pain and disability in spite of the reduction of new DUs.
Fold difference ratios from RT-qPCR results showed that twelve transcripts were congruent with the microarray results, while four genes gave no difference and four genes yielded conflicting results (Table 2).
The Wilcoxon Signed Rank Test applied to the experimental sample, with 28 pairs of answers (two answer gave no differences), resulted in a Z-score equal to 3.65.
Methanolic extracts were more active against A. versicolor, Trichoderma viride, P. funiculosum, and P. ochrochloron, while aqueous extracts were better in all remaining cases (except, of course, A. ochraceus, which gave no differences).
Based on the pharmacokinetic studies (supplementary), the predicted area under the curve for this experiment was 6 μℳ·h, given no strain difference and linear pharmacokinetics.
Given no strain difference and linear pharmacokinetics, a similar exposure in NMRI mice as in the C57 black mice would be expected.
It is important to emphasize that given no observed difference in OS between axitinib and sorafenib, the overall benefit compared to sorafenib appears modest in the postsunitinib setting.
Given no significant difference between medication and placebo we calculated the effect size of improvement in functioning for all participants at 15 weeks which was.5, and.44 at 20 weeks.
Given no significant difference in glycaemic control and applying the additional effectiveness of exenatide over insulin glargine, with respect to weight loss, and using the current UK NHS prices, insulin glargine was found to be dominant over exenatide in all modelled scenarios.
